XHKG1952
Market cap1.96bUSD
Dec 23, Last price
46.80HKD
1D
0.65%
1Q
92.99%
IPO
-39.34%
Name
Everest Medicines Ltd
Chart & Performance
P/E
—
P/S
113.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.99%
Rev. gr., 5y
%
Revenues
126m
+884.46%
Net income
-844m
L+241.50%
CFO
-769m
L-33.45%
Earnings
Mar 03, 2025
Profile
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 125,932 884.46% | 12,792 23,588.89% | 54 | |||
Cost of revenue | 971,042 | 1,417,615 | 1,054,282 | |||
Unusual Expense (Income) | ||||||
NOPBT | (845,110) | (1,404,823) | (1,054,228) | |||
NOPBT Margin | ||||||
Operating Taxes | 8 | 4,816 | ||||
Tax Rate | ||||||
NOPAT | (845,110) | (1,404,831) | (1,059,044) | |||
Net income | (844,463) 241.50% | (247,283) -75.60% | (1,013,535) -82.16% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 29,787 | 5,281 | (52,850) | |||
BB yield | -0.46% | -0.10% | 0.55% | |||
| Debt | ||||||
Debt current | 41,316 | 444,408 | 28,251 | |||
Long-term debt | 527,958 | 138,941 | 580,885 | |||
Deferred revenue | 6,053 | |||||
Other long-term liabilities | 28,614 | 30,923 | 26,778 | |||
Net debt | (1,829,347) | 3,319 | (2,861,320) | |||
| Cash flow | ||||||
Cash from operating activities | (769,190) | (1,155,761) | (729,936) | |||
CAPEX | (117,336) | (432,743) | (975,816) | |||
Cash from investing activities | 752,497 | (1,028,025) | (975,816) | |||
Cash from financing activities | 10,103 | (25,311) | (76,508) | |||
FCF | 498,569 | (3,178,702) | (1,226,144) | |||
| Balance | ||||||
Cash | 2,349,691 | 1,651,376 | 2,640,053 | |||
Long term investments | 48,930 | (1,071,346) | 830,403 | |||
Excess cash | 2,392,324 | 579,390 | 3,470,453 | |||
Stockholders' equity | (9,016,262) | 5,654,486 | 5,950,703 | |||
Invested Capital | 14,530,223 | 5,603,769 | 2,928,378 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 313,063 | 297,635 | 293,272 | |||
Price | 20.90 20.25% | 17.38 -46.69% | 32.60 -52.02% | |||
Market cap | 6,543,013 26.49% | 5,172,896 -45.89% | 9,560,672 64.85% | |||
EV | 4,713,666 | 5,176,215 | 6,699,352 | |||
EBITDA | (768,334) | (1,362,051) | (1,023,104) | |||
EV/EBITDA | ||||||
Interest | 23,059 | 5,591 | 4,816 | |||
Interest/NOPBT | ||||||